<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03473223</url>
  </required_header>
  <id_info>
    <org_study_id>CSL112_3001</org_study_id>
    <nct_id>NCT03473223</nct_id>
  </id_info>
  <brief_title>Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome</brief_title>
  <acronym>AEGIS-II</acronym>
  <official_title>A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group
      study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV
      events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects
      with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation myocardial
      infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), including
      those managed with percutaneous coronary intervention (PCI) or medically managed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first occurrence of any component of composite MACE (CV death, MI, or stroke )</measure>
    <time_frame>Through 90 days</time_frame>
    <description>MACE [Major adverse cardiovascular event(s)][ (CV (cardiovascular)death, MI (Myocardial Infarction), or stroke)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Key secondary outcome: Total number of hospitalizations for coronary, cerebral, or peripheral ischemia</measure>
    <time_frame>Through 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Key secondary outcome: Time to first occurrence of CV death, MI, or stroke</measure>
    <time_frame>Through 180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Key secondary outcome: Time to first occurrence of CV death, MI, or stroke</measure>
    <time_frame>Through 365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to occurrence of CV death</measure>
    <time_frame>Through 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence of MI</measure>
    <time_frame>Through 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence of stroke</measure>
    <time_frame>Through 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to occurrence of all-cause death</measure>
    <time_frame>Through 365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>Through 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects with adverse events</measure>
    <time_frame>Through 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with treatment-related adverse events</measure>
    <time_frame>Through 365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects with treatment-related adverse events</measure>
    <time_frame>Through 365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with serious adverse events</measure>
    <time_frame>Through 365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects with serious adverse events</measure>
    <time_frame>Through 365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with a shift in clinical laboratory assessments from baseline to worst post-treatment value according to normal range criteria (normal, high, or low)</measure>
    <time_frame>Baseline and 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects with a shift in clinical laboratory assessments from baseline to worst post-treatment value according to normal range criteria (normal, high, or low)</measure>
    <time_frame>Baseline and 29 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">17400</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>CSL112</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apolipoprotein A-I [human]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>25% albumin solution diluted to 4.4%</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Apolipoprotein A-I [human] (apoA-I)</intervention_name>
    <description>Apolipoprotein A-I [human] (apoA-I) purified from human plasma for intraveneous administration</description>
    <arm_group_label>CSL112</arm_group_label>
    <other_name>CSL112</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>25% albumin solution diluted to 4.4%</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female least 18 years of age

          -  Evidence of myocardial necrosis, consistent with type I (spontaneous) MI

          -  No suspicion of acute kidney injury

          -  Evidence of multivessel coronary artery disease and at least 1 of the following
             established risk factors:age â‰¥ 65 years, prior history of MI, diabetes mellitus,or
             peripheral artery disease

        Exclusion Criteria:

          -  Ongoing hemodynamic instability

          -  Evidence of hepatobiliary disease

          -  Evidence of severe chronic kidney disease

          -  Plan to undergo scheduled coronary artery bypass graft surgery

          -  Known history of allergies, hypersensitivity, or deficiencies to soy bean, peanut or
             albumin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail Berman</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring - Director, Medical Affairs Cardiovascular</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Registration Coordinator</last_name>
    <phone>610-878-4000</phone>
    <email>clinicaltrials@cslbehring.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>8400522 - California Heart Specialists</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92648</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>8400658 - Valley Clinical Trials, Inc.</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>8400371 - Danbury Hospital</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>8400517 - Shands Jacksonville Medical Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>8400368 - Cambridge Medical Trials</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>8400638 - Mid Michigan Regional Medical Center</name>
      <address>
        <city>Midland</city>
        <state>Michigan</state>
        <zip>48670</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>8400364 - Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>8400631 - North Kansas City Hospital</name>
      <address>
        <city>North Kansas City</city>
        <state>Missouri</state>
        <zip>64116</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>8400366 - High Point Regional Hospital</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>8400582 - Carolina Heart Specialists</name>
      <address>
        <city>Lancaster</city>
        <state>South Carolina</state>
        <zip>29720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>8400320 - Black Hills Cardiovascular Research</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>8400805 - PharmaTex Research</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>8400502 -Stroobants Cardiovascular Center</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>8400503 - The Heart and Vascular Center / Holy Family Memorial</name>
      <address>
        <city>Manitowoc</city>
        <state>Wisconsin</state>
        <zip>54220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>8400358 - Aspirus Research Institute</name>
      <address>
        <city>Wausau</city>
        <state>Wisconsin</state>
        <zip>54401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2018</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

